NextCure Inc. (NXTC)
NXTC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2020-12-31, https://www.sec.gov/Archives/edgar/data/1661059/000155837022002824/0001558370-22-002824-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2020-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NXTC on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2019 |
| SEC CIK | 0001661059 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2020
| Line | Value |
|---|---|
| Revenue | $22.4M |
| Net income | -$36.6M |
| Operating income | -$41.2M |
| Net margin | -163.6% |
| Operating margin | -184.2% |
| Revenue growth | +252.6% |
| Cash | $32.8M |
| Total assets | $306.6M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "Accordingly, management has concluded that substantial doubt exists about the Company's ability to continue as a going concern." | 10-Q 2026-11-10 |
| Cash and burn | $8.7M cash; operating cash flow -$10.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 4,579,023 (2026-11-09); 2,679,822 a year earlier; 27,903,027 three years earlier. 3y figure adjusted for split (1-for-12 overall). | Cover page 2026-11-09 |
| Reverse splits, 3 years | 1; latest 1-for-12 on 2025-07-14 | Source 2025-07-14 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2025-12-19 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Baltimore, Maryland, United States | PCAOB Form AP 2026-03-17 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.6M, sold $185K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$6.8M | -$12.1M | $8.7M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2026 2026-06-30 | Not filed | -$14.9M | -$9.7M | $15.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2026 2026-03-31 | Not filed | -$9.8M | -$13.4M | $15.2M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2025 2025-12-31 | Not filed | -$9.4M | -$7.6M | $26.0M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
| Q3 2025 2025-09-30 | Not filed | -$8.6M | -$6.3M | $7.3M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q2 2025 2025-06-30 | Not filed | -$26.8M | -$22.7M | $4.9M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q1 2025 2025-03-31 | Not filed | -$11.0M | -$13.0M | $21.8M | No debt tags | Needs four quarters | 10-Q 2026-11-10 |
| Q4 2024 2024-12-31 | Not filed | -$11.6M | -$7.0M | $27.7M | No debt tags | Needs four quarters | 10-K 2026-03-05 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-06 |
| Latest annual report | 10-K | 2026-03-05 |
| Latest quarterly / interim | 10-Q | 2026-11-10 |
| Latest current report | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 402 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +20.1% |
| 1 month | +1.9% |
| 3 months | -22.7% |
| Year to date | -54.9% |
| 1 year | -34.4% |
| From 52-week high | -55.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| NSRX | Nasus Pharma Ltd. | $2.66 | -7.32% | $31.2M |
| PMN | ProMIS Neurosciences Inc. Common Shares (ON) | $3.31 | +0.61% | $29.8M |
| NNVC | NanoViricides Inc. | $1.24 | +0.81% | $31.7M |
| SCYX | SCYNEXIS Inc. | $2.91 | -9.35% | $29.0M |
| BCTX | BriaCell Therapeutics Corp. Common Shares | $3.30 | -2.65% | $28.8M |
| AARD | Aardvark Therapeutics Inc. | $1.26 | -5.26% | $27.6M |
| RNTX | Rein Therapeutics Inc. | $0.4000 | -27.55% | $34.5M |
| RMTI | Rockwell Medical Inc. | $6.76 | -4.38% | $26.9M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier